The Latest Breaking News from GoodRx Holdings

 

 

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

Analysts have provided the following ratings for GoodRx Holdings (NASDAQ:GDRX) within the last quarter:

 

Upgrades

GoodRx Holdings (NASDAQ:GDRX) reported its Q1 earnings results on Monday, May 9, 2022 at 04:07 PM. Here's what investors need to know about the announcement. Earnings GoodRx Holdings beat estimated earnings by 25.0%, reporting an EPS of $0.1 versus an estimate of $0.08.

Over the past 3 months, 13 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Upgrades